May 2017:

Highlights in Ovarian Cancer From the 2017 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer

A Review of Selected Presentations From the 2017 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer March 12-15, 2017 • National Harbor, Maryland Special Reporting […]

April 2017:

Recent Advances in the Management of Gastroenteropancreatic Neuroendocrine Tumors: Insights From the 2017 ASCO Gastrointestinal Cancers Symposium

Clinical Advances in Hematology & Oncology April 2017, Volume 15, Issue 4, Supplement 4 Renuka Iyer, MD, Alexandria T. Phan, MD, and J. Philip Boudreaux, MD, FACS Abstract: […]

February 2017:

Perspectives in Chronic Lymphocytic Leukemia: A Post-ASH Update

Clinical Advances in Hematology & Oncology February 2017 Special Supplement Considerations in the Frontline Treatment of Chronic Lymphocytic Leukemia: A Post-ASH Update Susan M. O’Brien, MD […]

Highlights in Myeloproliferative Neoplasms From the 2016 American Society of Hematology Annual Meeting and Exposition

A Review of Selected Presentations From the 2016 American Society of Hematology Annual Meeting and Exposition December 3-6, 2016 • San Diego, California PLUS  Meeting Abstract […]

Highlights in Lymphoma From the 2016 American Society of Hematology Annual Meeting and Exposition

A Review of Selected Presentations From the 2016 American Society of Hematology Annual Meeting and Exposition December 3-6, 2016 • San Diego, California PLUS  Meeting Abstract […]

December 2016:

Novel Second-Line Treatments for Hepatocellular Carcinoma

Moderator Richard S. Finn, MD Discussants Catherine T. Frenette, MD, FAST, and Riccardo Lencioni, MD Abstract: There are 3 management approaches for patients with newly diagnosed hepatocellular carcinoma […]

Highlights in GEP-NETs From the 2016 NANETS Symposium

A SPECIAL MEETING REVIEW EDITION A Review of Selected Presentations From the 2016 North American Neuroendocrine Tumor Society Annual Symposium September 30-October 1, 2016 • Jackson, […]

Highlights in Ovarian Cancer From the 2016 ESMO Congress

A SPECIAL MEETING REVIEW EDITION A Review of Selected Presentations From the 2016 European Society for Medical Oncology Congress October 7-11, 2016 • Copenhagen, Denmark A […]

Highlights in Chronic Lymphocytic Leukemia From the 2016 American Society of Hematology Annual Meeting and Exposition

Special Reporting on:
• Five-Year Experience With Single-Agent Ibrutinib in Patients With Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia
• Twice Daily Dosing With the Highly Specific BTK Inhibitor, BGB-3111, Achieves Complete and Continuous BTK Occupancy in Lymph Nodes, and Is Associated With Durable Responses in Patients (pts) With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
• Integrated and Long-Term Safety Analysis of Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
• Acalabrutinib Monotherapy in Patients With Ibrutinib Intolerance: Results From the Phase 1/2 ACE-CL-001 Clinical Study
• Updated Efficacy and Safety From the Phase 3 RESONATE-2 Study: Ibrutinib as First-Line Treatment Option in Patients 65 Years and Older With Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia
• Updated Analysis of Overall Survival in Randomized Phase III Study of Idelalisib in Combination With Bendamustine and Rituximab in Patients With Relapsed/Refractory CLL
• CLL2-BIG – A Novel Treatment Regimen of Bendamustine Followed By GA101 and Ibrutinib Followed by Ibrutinib and GA101 Maintenance in Patients With Chronic Lymphocytic Leukemia (CLL): Results of a Phase II-Trial
PLUS Meeting Abstract Summaries
With Expert Commentary by:
Susan M. O’Brien, MD
Associate Director for Clinical Sciences, Chao Family Comprehensive Cancer Center
Medical Director, Sue and Ralph Stern Center for Clinical Trials & Research
Professor of Medicine, Division of Hematology/Oncology, Department of Medicine
University of California, Irvine, Orange, California

November 2016:

Atypical Hemolytic Uremic Syndrome (aHUS): Essential Aspects of an Accurate Diagnosis

Clinical Advances in Hematology & Oncology Volume 14, Issue 11, Supplement 11, November 2016 Authors: Jeffrey Laurence, MD Professor of Medicine Division of Hematology and Medical […]

August 2016:

Highlights in CINV From the 2016 MASCC/ISOO Annual Meeting

Clinical Advances in Hematology & Oncology August 2016, Volume 14, Issue 8, Supplement 10 Highlights in CINV From the 2016 MASCC/ISOO Annual Meeting A Review of […]

May 2016:

Progressive Differentiated Thyroid Cancer: Best Use of the Tyrosine Kinase Inhibitors

Volume 14, Issue 5, Supplement 9 May 2016 Moderator Marcia S. Brose, MD, PhD Director, Center for Rare Cancers and Personalized Therapy Abramson Cancer Center Associate […]

The Changing Landscape in the Frontline Treatment of Chronic Lymphocytic Leukemia

Volume 14, Issue 5, Supplement 8 May 2016 Discussants John M. Pagel, MD, PhD Chief, Hematologic Malignancies Director, Hematopoietic Stem Cell Transplantation Program Swedish Cancer Institute […]

Highlights in GEP-NETs From the 13th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease

Volume 14, Issue 5, Supplement 7 May 2016 Highlights in GEP-NETs From the 13th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease […]

April 2016:

Current Concepts in the Management of GEP-NETs: A Case Study Compendium

Volume 14, Issue 4, Supplement 6  April 2016 Current Concepts in the Management of GEP-NETs: A Case Study Compendium Discussants Renuka Iyer, MD Associate Professor of […]

Highlights in Metastatic Prostate Cancer From the 2016 American Society of Clinical Oncology Genitourinary Cancers Symposium

Volume 14, Issue 4, Supplement 5  April 2016 A SPECIAL MEETING REVIEW EDITION Highlights in Metastatic Prostate Cancer From the 2016 American Society of Clinical Oncology […]

Novel Approaches for the Interim Management of Relapsed/Refractory Acute Lymphocytic Leukemia: A Case-Study Compendium

Volume 14, Issue 3, Supplement 4  March 2016 Novel Approaches for the Interim Management of Relapsed/Refractory Acute Lymphocytic Leukemia: A Case-Study Compendium Moderator Eunice S. Wang, […]

March 2016:

Current Options for Third-Line Treatment of Metastatic Colorectal Cancer

Recent Clinical Trials in Relapsed/Refractory Metastatic Colorectal Cancer John L. Marshall, MD Chief, Division of Hematology/Oncology Director, Ruesch Center for the Cure of Gastrointestinal Cancers Lombardi […]

Highlights in GEP-NETs From the 2016 American Society of Clinical Oncology Gastrointestinal Cancers Symposium

Rare Tumors of the Upper GI Tract: Neuroendocrine Tumors At the 2016 American Society of Clinical Oncology Gastro-intestinal Cancers Symposium (ASCO GI), Dr Jennifer Eads discussed […]

February 2016:

Highlights in Lymphoma From the 2015 American Society of Hematology Annual Meeting and Exposition

A Review of Selected Presentations From the 2015 American Society of Hematology Annual Meeting and Exposition • December 5-8, 2015 • Orlando, Florida Special Reporting on: […]

December 2015:

Strategies for the Management of Hepatic Veno-Occlusive Disease in Patients Undergoing Bone Marrow Transplant

Clinical Advances in Hematology & Oncology Volume 13, Issue 12, Supplement 12 December 2015 Moderator Paul G. Richardson, MD Clinical Program Leader and Director of Clinical […]

November 2015:

Technological Advances in the Treatment of Cancer: Combining Modalities to Optimize Outcomes

Clinical Advances in Hematology & Oncology Volume 13, Issue 11, Supplement 11 November 2015 Moderator Eric T. Wong, MD Associate Professor, Neurology Harvard Medical School Co-Director, […]

October 2015:

Advances in the Management of Chemotherapy-Induced Nausea and Vomiting: New Data From Recent and Ongoing Trials

Volume 13, Issue 10, Supplement 10  October 2015 Discussants Eric Roeland, MD Director of Clinical Research in Symptom Intervention Assistant Clinical Professor of Medicine University of […]

August 2015:

Highlights in Lymphoma From the 13th International Conference on Malignant Lymphoma

Volume 13, Issue 8, Supplement 9  August 2015 Highlights in Lymphoma From the 13th International Conference on Malignant Lymphoma A Review of Selected Presentations From the […]

Highlights in GEP-NETs From the 2015 American Society of Clinical Oncology Annual Meeting

Volume 13, Issue 8, Supplement 8  August 2015 Highlights in GEP-NETs From the 2015 American Society of Clinical Oncology Annual Meeting A Review of Selected Presentations […]

June 2015:

Novel Management Options for Adult Patients With Progressive Acute Lymphoblastic Leukemia: A Case-Study Compendium

Volume 13, Issue 6, Supplement 7  June 2015 Novel Management Options for Adult Patients With Progressive Acute Lymphoblastic Leukemia: A Case-Study Compendium Moderator Eunice S. Wang, […]

Emerging Data on Multianalyte Algorithm Assays in Breast Cancer: A Clinical Review

Volume 13, Issue 6, Supplement 6  June 2015 Emerging Data on Multianalyte Algorithm Assays in Breast Cancer: A Clinical Review Faculty Ralph V. Boccia, MD Medical […]

May 2015:

New and Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors

Moderator Alexandria T. Phan, MD Director of GI Medical Oncology Houston Methodist Cancer Center Houston, Texas   Discussants Pamela L. Kunz, MD Assistant Professor of Medicine […]

April 2015:

New and Emerging Therapeutic Options for Thyroid Carcinoma

Clinical Advances in Hematology & Oncology April 2015, Volume 13, Issue 4, Supplement 4   Discussants Jatin P. Shah, MD Chief, Head and Neck Service, Elliot W. […]

March 2015:

New and Emerging Therapeutic Options for the Management of Chemotherapy-Induced Nausea and Vomiting

Clinical Advances in Hematology & Oncology March 2015, Volume 13, Issue 3, Supplement 3   Discussants: Lee S. Schwartzberg, MD, Professor of Medicine, Chief, Division of Hematology & […]

February 2015:

Managing Risk in Hodgkin Lymphoma

Clinical Advances in Hematology & Oncology February 2015, Volume 13, Issue 2, Supplement 1   Clinical Roundtable Monograph   Discussants James O. Armitage, MD Professor, Department […]

Highlights in Lymphoma From the 2014 American Society of Hematology Annual Meeting and Exposition

Clinical Advances in Hematology & Oncology February 2015, Volume 13, Issue 2, Supplement 2   A Review of Selected Presentations From the 2014 American Society of […]

December 2014:

Beyond Symptom Control: Continued Advances in Targeting Gastroenteropancreatic Neuroendocrine Tumors

December 2014, Volume 12, Issue 12, Supplement 19 Beyond Symptom Control: Continued Advances in Targeting Gastroenteropancreatic Neuroendocrine Tumors A Review of a Satellite Symposium of the 2014 European Society for […]

Advances in the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: A Case Study Compendium

December 2014, Volume 12, Issue 12, Supplement 20 Advances in the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: A Case Study Compendium Faculty Gail J. Roboz, MD […]

October 2014:

Highlights in NSCLC From the 2014 American Society of Clinical Oncology Annual Meeting

October 2014, Volume 12, Issue 10, Supplement 18 A Review of Selected Presentations From the 2014 American Society of Clinical Oncology Annual Meeting • May 30-June […]

September 2014:

Highlights in Advanced Prostate Cancer From the 2014 AUA and ASCO Meetings

September 2014, Volume 12, Issue 9, Supplement 17 A Review of Selected Presentations From the 2014 American Urological Association Meeting, May 16-21, 2014, Orlando, Florida and […]

August 2014:

Highlights in Lymphoma From the 2014 European Hematology Association Congress

August 2014, Volume 12, Issue 8, Supplement 16 A Review of Selected Presentations From the 2014 European Hematology Association Congress • June 12-15, 2014 • Milan, […]

A Review of an Adjunct Symposium of the 2014 American Society of Clinical Oncology Annual Meeting

Clinical Advances in Hematology & Oncology August 2014, Volume 12, Issue 8, Supplement 15   Evidence-Driven, Patient-Specific Approaches for Optimizing Survival Prolongation in  Breast Cancer May […]

July 2014:

A Review of an Adjunct Symposium of the 2014 American Society of Clinical Oncology Annual Meeting

July 2014, Volume 12, Issue 7, Supplement 14 New Frontiers and Treatment Paradigms for Thyroid Carcinoma Distinguished Program ChairmenRobert Haddad, MD Associate Professor, Department of Medicine, Harvard Medical […]

Clinical Roundtable Monograph: Integrating Current Treatment Options for TKI-Resistant Chronic Myeloid Leukemia

July 2014, Volume 12, Issue 7, Supplement 13 Discussants Jerald P. Radich, MD Director, Molecular Oncology Lab, Clinical Research Division, Fred Hutchinson Cancer Research Center, Professor of Medicine and […]

June 2014:

New Developments in Acute Lymphoblastic Leukemia

June 2014, Volume 12, Issue 6, Supplement 12 Highlights in Acute Lymphoblastic Leukemia From the 2013 American Society of Hematology Annual Meeting and Exposition  Discussants Dan […]

April 2014:

Highlights in Advanced Prostate Cancer From the 2014 American Society of Clinical Oncology Genitourinary Cancers Symposium

Daniel J. George, MD

Volume 12, Issue 4, Supplement 11  April 2014 Highlights in Advanced Prostate Cancer From the 2014 American Society of Clinical Oncology Genitourinary Cancers Symposium A Review […]

Clinical Roundtable Monograph: CD30 in Lymphoma: Its Role in Biology, 
Diagnostic Testing, and Targeted Therapy

Eduardo M. Sotomayor, MD, Ken H. Young, MD, PhD, Anas Younes, MD

Volume 12, Issue 4, Supplement 10  April 2014 Discussants Eduardo M. Sotomayor, MD Susan and John Sykes Endowed Chair in Hematologic Malignancies Moffitt Cancer Center Scientific […]

March 2014:

Clinical Roundtable Monograph: New Data in Emerging Treatment Options for Chemotherapy-Induced Nausea and Vomiting

Gary R. Morrow, PhD, MS, Rudolph M. Navari, MD, PhD, Hope S. Rugo, MD

Volume 12, Issue 3, Supplement 9  March 2014 Clinical Roundtable Monograph: New Data in Emerging Treatment Options for Chemotherapy-Induced Nausea and Vomiting Discussants Gary R. Morrow, PhD, […]

Highlights in Metastatic Breast Cancer From the 2013 San Antonio Breast Cancer Symposium (SABCS)

Joyce A. O’Shaughnessy, MD

Volume 12, Issue 3, Supplement 7  March 2014 Highlights in Metastatic Breast Cancer From the 2013 San Antonio Breast Cancer Symposium (SABCS) A Review of Selected […]

February 2014:

Highlights in Lymphoma From the 2013 American Society of Hematology Annual Meeting and Exposition

Highlights in Lymphoma From the 2013 American Society of Hematology Annual Meeting and Exposition A Review of Selected Presentations From the 2013 American Society of Hematology Annual Meeting […]

Highlights in T-Cell Lymphoma From the 2013 American Society of Hematology Annual Meeting and Exposition

A SPECIAL MEETING REVIEW EDITION Highlights in T-Cell Lymphoma From the 2013 American Society of Hematology Annual Meeting and Exposition A Review of Selected Presentations From the 2013 American […]

Clinical Roundtable Monograph: Effective Management of Quality of Life in Metastatic Breast Cancer

Effective Management of Quality of Life in Metastatic Breast Cancer Moderator: Christopher Twelves, MD, Professor of Clinical Pharmacology and Oncology, Head, Clinical Cancer Research Groups, Leeds Institute of Cancer Studies […]

January 2014:

Clinical Roundtable Monograph: Unmet Needs in the Treatment of Chronic Lymphocytic Leukemia: Integrating a Targeted Approach

Unmet Needs in the Treatment of Chronic Lymphocytic Leukemia: Integrating a Targeted Approach Moderator: Susan M. O’Brien, MD, Ashbel Smith Professor, Department of Leukemia, Division of Cancer Medicine, UT MD Anderson Cancer […]

Clinical Roundtable Monograph: Diagnostic Dilemmas That Impact Treatment Decisions in Lymphoma

Diagnostic Dilemmas That Impact Treatment Decisions in Lymphoma Case Presenters: Randy D. Gascoyne, MD Clinical Professor of Pathology – UBC, Hematopathologist – BC Cancer Agency, Medical Director, Provincial Lymphoma Pathology Program, Research […]

Highlights in NSCLC From the 15th World Conference on Lung Cancer

Volume 12, Issue 1, Supplement 1   January 2014  Highlights in NSCLC From the 15th World Conference on Lung Cancer A Review of Selected Presentations From the […]

December 2013:

Clinical Roundtable Monograph: Integrating Emerging Treatment Options in Mantle Cell Lymphoma

Brad S. Kahl, MD, Nathan H. Fowler, MD, Myron S. Czuczman, MD

Volume 11, Issue 12, Supplement 19  December 2013 Clinical Roundtable Monograph: Integrating Emerging Treatment Options in Mantle Cell Lymphoma Moderator Brad S. Kahl, MD Skoronski Chair of Lymphoma […]

October 2013:

Clinical Roundtable Monograph: Unmet Needs in the Treatment of Mantle Cell Lymphoma

Steven T. Rosen, MD, Brian K. Link, MD, and Brian K. Link, MD

Volume 11, Issue 11, Supplement 18  November 2013 Unmet Needs in the Treatment of Mantle Cell Lymphoma   Moderator Steven T. Rosen, MD Director, Robert H. […]

Clinical Roundtable Monograph: Sequential Therapy in Chronic Myelogenous Leukemia: Where Do Emerging Therapies Fit Within Current Treatment Regimens?

Michael J. Mauro, MD, Moshe Talpaz, MD, and Jerald P. Radich, MD

Volume 11, Issue 11, Supplement 17  November 2013 Sequential Therapy in Chronic Myelogenous Leukemia: Where Do Emerging Therapies Fit Within Current Treatment Regimens? Moderator Michael J. […]

Clinical Roundtable Monograph: New Developments in Metastatic Breast Cancer: Integrating Recent Data into Clinical Practice

Edith A. Perez, MD, Hope S. Rugo, MD, and Linda T. Vahdat, MD

Volume 11, Issue 10, Supplement 16  October 2013 New Developments in Metastatic Breast Cancer: Integrating Recent Data into Clinical Practice Moderator Edith A. Perez, MD Deputy […]

Atypical Hemolytic Uremic Syndrome (aHUS): Treating the Patient

Jeffrey Laurence, MD

Volume 11, Issue 10, Supplement 15  October 2013 Atypical Hemolytic Uremic Syndrome (aHUS): Treating the Patient Plus: A Review of Case Studies Jeffrey Laurence, MD Professor of […]

September 2013:

Highlights in Lymphoma From the 12th International Conference on Malignant Lymphoma: A Review of Selected Presentations From the 12th International Conference on Malignant Lymphoma

Volume 11, Issue 9, Supplement 14  September 2013 Highlights in Lymphoma From the 12th International Conference on Malignant Lymphoma A Review of Selected Presentations From the […]

Paroxysmal Nocturnal Hemoglobinuria: Pathogenesis, Testing, and Diagnosis

Vivek R. Sharma, MD; Sameer S. Talwalkar, MD

Volume 11, Issue 9, Supplement 13  September 2013 Paroxysmal Nocturnal Hemoglobinuria: Pathogenesis, Testing, and Diagnosis Plus a Case Report and a Q&A on the Role of […]

Advancements in the Treatment of B-Cell Malignancies

Volume 11, Issue 9, Supplement 12  September 2013 Advancements in the Treatment of B-Cell Malignancies International Conference on Malignant Lymphoma Lugano, Switzerland • June 18, 2013 […]

August 2013:

Highlights in Advanced Prostate Cancer From the 2013 American Urological Association Annual Meeting and the 2013 American Society of Clinical Oncology Annual Meeting

Daniel J. George, MD, Andrew J. Armstrong, MD, ScM, Michael R. Harrison, MD

Volume 11, Issue 8, Supplement 11  August 2013 Highlights in Advanced Prostate Cancer From the 2013 American Urological Association Annual Meeting and the 2013 American Society […]

Individualizing Treatment to Optimize Survival Outcomes in Breast Cancer

Edith A. Perez, MD, William J. Gradishar, MD, Christopher Twelves, MD, Lee Schwartzberg, MD

Volume 11, Issue 8, Supplement 10  August 2013 Individualizing Treatment to Optimize Survival Outcomes in Breast Cancer A Review of an Adjunct Symposium of the 2013 […]

Clinical Roundtable Monograph: The Importance of the BTK Pathway in B-Cell Malignancies

John C. Byrd, MD, Jan A. Burger, MD, PhD, Adrian Wiestner, MD, PhD

Volume 11, Issue 8, Supplement 9  August 2013 Clinical Roundtable Monograph The Importance of the BTK Pathway in B-Cell Malignancies Moderator John C. Byrd, MD D. […]

April 2013:

Highlights in Advanced Prostate Cancer From the 2013 American Society of Clinical Oncology Genitourinary Cancers Symposium

Axel Grothey, MD

Volume 11, Issue 4, Supplement 7  April 2013 Highlights in Advanced Prostate Cancer From the 2013 American Society of Clinical Oncology Genitourinary Cancers Symposium February 14–16, […]

Highlights in Metastatic Colorectal Cancer From the 2013 American Society of Clinical Oncology Gastrointestinal Cancers Symposium

Oliver Sartor, MD

Volume 11, Issue 4, Supplement 8  April 2013 Highlights in Metastatic Colorectal Cancer From the 2013 American Society of Clinical Oncology Gastrointestinal Cancers Symposium January 14–16, […]

Highlights in B-Cell Malignancies From the 2012 American Society of Hematology (ASH) Meeting

Susan M. O’Brien, MD, Luhua (Michael) Wang, MD

Volume 11, Issue 4, Supplement 6  April 2013 Highlights in B-Cell Malignancies From the 2012 American Society of Hematology (ASH) Meeting A Review of Selected Presentations […]

Extending Survival With the Use of Targeted Therapy in the Treatment of Hepatocellular Carcinoma

Robert G. Gish, MD, Richard S. Finn, MD, Jorge A. Marrero, MD, MS

Volume 11, Supplement 5, April 2013 Extending Survival With the Use of Targeted Therapy in the Treatment of Hepatocellular Carcinoma Moderator Robert G. Gish, MD Chief, Section […]

March 2013:

Highlights in Metastatic Breast Cancer From the 2012 San Antonio Breast Cancer Symposium (SABCS)

Peter A. Kaufman, MD

Volume 11, Issue 3, Supplement 4  March 2013 A Review of Selected Presentations From the 2012 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) December 4–8, 2012 • San […]

February 2013:

Highlights in Lymphoma From the 2012 American Society of Hematology Annual Meeting and Exposition

Michelle A. Fanale, MD

Volume 11, Issue 2, Supplement 3  February 2013 A Review of Selected Presentations From the 54th Annual Meeting and Exposition • December 8–11, 2012 • Atlanta, […]

Highlights in the Management of Breast Cancer From the 2012 San Antonio Breast Cancer Symposium (SABCS)

Hope S. Rugo, MD

Volume 11, Issue 2, Supplement 2  February 2013 A Review of Selected Presentations From the 2012 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) December 4–8, 2012 […]

Emerging Treatments in Chemotherapy-Induced Nausea and Vomiting

Steven M. Grunberg, MD, Barbara Slusher, PhD, Hope S. Rugo, MD

Volume 11, Issue 2, Supplement 1  February 2013 Emerging Treatments in Chemotherapy-Induced Nausea and Vomiting Moderator Steven M. Grunberg, MD Professor of Medicine The University of […]

December 2012:

Clinical Roundtable Monograph: Unmet Needs in the Management of Chronic Myelogenous Leukemia

Elias J. Jabbour, MD, Dale Bixby, MD, PhD, and Luke P. Akard, MD

Abstract: Approximately 5,000 cases of chronic myelogenous leukemia (CML) are diagnosed each year in the United States. The introduction of tyrosine kinase inhibitors (TKIs) has dramatically improved survival time for many CML patients. Current first-line treatment options include imatinib and the second-generation agents nilotinib and dasatinib. Second- and third-line agents include nilotinib, dasatinib, bosutinib, and the new agent ponatinib. Despite the effectiveness of TKIs, some patients develop resistance or intolerance to these agents. A number of mutations of the BCR-ABL gene have been identified and are associated with TKI resistance. Patients may benefit from switching to a second-line TKI, undergoing hematopoietic stem cell transplant, or receiving newly emerging agents. Although early response is associated with improved patient outcome, clinicians lack tests that can determine which patients will benefit from which therapies. To ensure adequate response, patients should be monitored by both polymerase chain reaction and cytogenetic analysis of the bone marrow. This roundtable monograph reviews key unmet needs in patients with CML related to disease management and treatment options.

November 2012:

Clinical Roundtable Monograph: Paroxysmal Nocturnal Hemoglobinuria: A Case-Based Discussion

Jeff Szer, MBBS, FRACP, Anita Hill, MBChB (Hons), MRCP, FRCPath, PhD, and Ilene Ceil Weitz, MD

Abstract: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired disorder characterized by chronic intravascular hemolysis as the primary clinical manifestation and morbidities that include anemia, thrombosis, renal impairment, pulmonary hypertension, and bone marrow failure. The prevalence of the PNH clone (from <1–100% PNH granulocytes) is approximately 16 per million, and careful monitoring is required. The average age of onset of the clinical disease is the early 30s, although it can present at all ages. PNH is caused by the acquisition of a somatic mutation of the gene phosphatidylinositol glycan anchor (PIG-A) in a multipotent hematopoietic stem cell (HSC), with clonal expansion of the mutated HSC. The mutation causes a deficiency in the synthesis of glycosylphosphatidylinositol (GPI). In cells derived from normal HSCs, the complement regulatory proteins CD55 and CD59 are anchored to the hematopoietic cell membrane surface via GPI, protecting the cells from complement-mediated lysis. However, in patients with PNH, these 2 proteins, along with numerous other GPI-linked proteins, are absent from the cell surface of red cells, granulocytes, monocytes, and platelets, resulting in complement-mediated intravascular hemolysis and other complications. Lysis of red blood cells is the most obvious manifestation, but as other cell lineages are also affected, this complement-mediated attack contributes to additional complications, such as thrombosis. Eculizumab, a humanized monoclonal antibody against the C5 complement protein, is the only effective drug therapy for PNH patients. The antibody prevents cleavage of the C5 protein by C5 convertase, in turn preventing generation of C5b-9 and release of C5a, thereby protecting from hemolysis of cells lacking the CD59 surface protein and other complications associated with complement activation. Drs. Ilene C. Weitz, Anita Hill, and Jeff Szer discuss 3 recent cases of patients with PNH.

Highlights in NSCLC From the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology

Corey J. Langer, MD, FACP

September 6–8, 2012 • Chicago, Illinois
Special Reporting on:
• Weekly nab-Paclitaxel in Combination With Carboplatin as First-Line Therapy For Advanced Non-Small Cell Lung Cancer
• Results of a Global Phase II Study With Crizotinib in Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
• A Randomized, Open-label, Phase 3, Superiority Study Of Pemetrexed (Pem)+Carboplatin (Cb)+Bevacizumab (B) Followed By Maintenance Pem+B Versus Paclitaxel (Pac)+Cb+B Followed By Maintenance B In Patients (pts) With Stage IIIB Or IV Non-squamous Non-small Cell Lung Cancer (NS-NSCLC)
• The Select Study: a Multicenter Phase II Trial of Adjuvant Erlotinib in Resected Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer (NSCLC)
• Clinical Activity and Safety of Anti-PD-1 (BMS-936558, MDX-1106) in Patients (Pts) With Advanced Non-Small-Cell Lung Cancer (NSCLC)
• Clinical Activity of Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring ROS1 Gene Rearrangement
• LUX-Lung 3: A Randomized, Open-Label, Phase III Study of Afatinib vs Pemetrexed and Cisplatin as First-Line Treatment For Patients With Advanced Adenocarcinoma of the Lung Harboring EGFR-Activating Mutations (Subgroup Analysis)
PLUS Meeting Abstract Summaries
With Expert Commentary by:
Corey J. Langer, MD, FACP Professor of Medicine Hematology-Oncology Division University of Pennsylvania Philadelphia, Pennsylvania

October 2012:

Clinical Roundtable Monograph: Emerging Treatment Options for TKI-Resistant Chronic Myelogenous Leukemia

Jorge Cortes, MD, Jerald Radich, MD, and Michael J. Mauro, MD

Abstract: The development of tyrosine kinase inhibitors (TKIs) that inhibit signaling of the constitutive BCR-ABL protein revolutionized the treatment of chronic myelogenous leukemia (CML). These agents have dramatically changed the treatment landscape for CML, shifting the use of allogeneic stem cell transplantation to selected patients in the salvage setting. Four BCR-ABL TKIs are now commercially available for the treatment of CML: the first-generation TKI imatinib, and the second-generation TKIs dasatinib, nilotinib, and bosutinib. Continuous treatment with these agents induces durable responses in a high proportion of patients with chronic-phase CML. Research is focused on identifying which patients can discontinue therapy without a recurrence of disease. For the group of patients with resistance to TKIs, multiple alternative therapies are being evaluated. The third-generation TKI ponatinib is a BCR-ABL inhibitor that has demonstrated significant activity, including in patients with the TKI resistance mutation T315I. The homoharringtonine derivative omacetaxine mepesuccinate, which inhibits protein synthesis, has also demonstrated clinical activity in CML, including in patients with TKI resistance due to T315I and in patients who have TKI resistance despite no evidence of ABL mutations. It is essential that clinicians implement these new agents with care and change therapies only when appropriate in order to preserve as many options as possible for future use if needed.

Clinical Roundtable Monograph: Recent Advances in Taxanes for the First-Line Treatment of Advanced Non–Small Cell Lung Cancer

Mark A. Socinski, MD, Ramaswamy Govindan, MD, and David Spigel, MD

Abstract: Treatments for non–small cell lung cancer (NSCLC) are based on the broad categories of squamous or non-squamous histology. Frontline treatment options include pemetrexed and cisplatin, pemetrexed and a taxane, gemcitabine with cisplatin, and the addition of bevacizumab to a taxane and carboplatin. Pemetrexed is used for maintenance therapy for non-squamous NSCLC, whereas patients with squamous NSCLC lack easy options for maintenance therapy. nab®-Paclitaxel overcomes the solubility and toxicity issues of solvent- based paclitaxel, and the albumin in nab-paclitaxel improves the concentration of the drug in the tumor. A recent phase III trial in NSCLC compared nab-paclitaxel with carboplatin versus solvent-based paclitaxel with carboplatin, and found improved overall response rates (ORRs) in the nab-paclitaxel arm (33% vs 25%; P=.005). In a subset analysis, NSCLC patients with squamous histology had a higher ORR (41%) with nab-paclitaxel than with solvent-based paclitaxel (24%; P<.001). Another subset analysis found that patients ages 70 years and older had improved overall survival (median 19.9 months) with nab-paclitaxel compared with solvent-based paclitaxel (median 10.4 months; P=.009). Patients in the nab-paclitaxel arm had less neuropathy, less hearing loss, and fewer interruptions in daily living than patients in the solvent-based paclitaxel arm.

Atypical Hemolytic Uremic Syndrome (aHUS): Making the Diagnosis

Jeffrey Laurence, MD

Volume 10, Issue 10, Supplement 17 October 2012 Atypical Hemolytic Uremic Syndrome (aHUS): Making the Diagnosis Plus: A Review of Case Studies Jeffrey Laurence, MD Professor […]

September 2012:

Highlights in Lymphoma From the 2012 European Hematology Association Annual Meeting

Robert Chen, MD

Volume 10, Issue 9, Supplement 16  September 2012 Highlights in Lymphoma From the 2012 European Hematology Association Annual Meeting June 14–17, 2012  ·  Amsterdam, The Netherlands […]

Highlights in Renal Cell Carcinoma From the 2012 American Society of Clinical Oncology Annual Meeting

Brian I. Rini, MD

Volume 10, Issue 9, Supplement 15  September 2012 Highlights in Renal Cell Carcinoma From the 2012 American Society of Clinical Oncology Annual Meeting June 1–5, 2012  […]

Highlights in Metastatic Breast Cancer From the 2012 American Society of Clinical Oncology Annual Meeting

Edith A. Perez, MD

Volume 10, Issue 9, Supplement 14  September 2012 Highlights in Metastatic Breast Cancer From the 2012 American Society of Clinical Oncology Annual Meeting June 1–5, 2012  […]

August 2012:

New Treatment Paradigms for Optimizing Survival in Advanced and Metastatic Breast Cancer

Edith A. Perez, MD, Howard A. Burris, III, MD, FACP, Susan Mooberry, PhD, and Debu Tripathy, MD

Volume 10, Issue 8, Supplement 13  August 2012 New Treatment Paradigms for Optimizing Survival in Advanced and Metastatic Breast Cancer A Review of an Adjunct Symposium […]

Highlights in Advanced Prostate Cancer From the 2012 American Urological Association Annual Meeting and the 2012 American Society of Clinical Oncology Annual Meeting

Neal D. Shore, MD, FACS

Volume 10, Issue 8, Supplement 12  August 2012 Highlights in Advanced Prostate Cancer From the 2012 American Urological Association Annual Meeting and the 2012 American Society of […]

Highlights in NSCLC From the 2012 American Society of Clinical Oncology Annual Meeting

Mark A. Socinski, MD

Volume 10, Issue 8, Supplement 11  August 2012 Highlights in NSCLC From the 2012 American Society of Clinical Oncology Annual Meeting June 1–5, 2012  •  Chicago, […]

Clinical Roundtable Monograph: Antibody-Drug Conjugate Technology Development for Hematologic Disorders

Neil H. Bander, MD, Myron S. Czuczman, MD, and Anas Younes, MD

Abstract: Antibody-drug conjugates (ADCs) combine cytotoxic chemotherapy and antibody specificity. There are 4 components of ADC technology: the cancer, or target, antigen; the antibody to that target; the linker that connects the drug to the antibody; and the drug itself. The antibody directs the cytotoxic agent to the tumor cell, thereby diminishing the side effect profile of the cytotoxic agent and enabling delivery of a more potent therapeutic because of the ability to control the target and the side effects. ADC technology has vastly improved within the last several years. In early ADCs, the linkers were too labile, which led to the release of free drug in the circulation and consequent off-target toxicity. In the current generation of ADCs, the linkers are more stable, and the cytotoxic agents are significantly more potent. ADCs have been developed against a variety of antigens and receptors, including CD19, CD22, and CD30, and have been linked to multiple different cytotoxic agents, including calicheamicin and maytansinoid derivatives. The ADC brentuximab vedotin was recently approved by the US Food and Drug Administration for the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant or at least 2 prior multiagent chemotherapy regimens, and the treatment of patients with systemic anaplastic large cell lymphoma after failure of at least 1 prior multiagent chemotherapy regimen. Other ADCs in clinical trials for hematologic disorders include inotuzumab ozogamicin, SAR3419, and gemtuzumab ozogamicin.

July 2012:

Highlights in Metastatic Colorectal Cancer From the 2012 American Society of Clinical Oncology Annual Meeting

Axel Grothey, MD

Special Reporting on:
• Bevacizumab (BEV) Plus Chemotherapy (CT) Continued Beyond First Progression in Patients With Metastatic Colorectal Cancer (mCRC) Previously Treated With BEV Plus CT: Results of a Randomized Phase III Intergroup Study (TML Study)
• Bevacizumab (Bev) With or Without Erlotinib as Maintenance Therapy, Following Induction First-Line Chemotherapy Plus Bev, in Patients (Pts) With Metastatic Colorectal Cancer (MCRC): Efficacy and Safety Results of the International GERCOR DREAM Phase III Trial
• Results of the X-PECT Study: A Phase III Randomized Double-Blind, Placebo-Controlled Study of Perifosine Plus Capecitabine (P-CAP) Versus Placebo Plus Capecitabine (CAP) in Patients (Pts) With Refractory Metastatic Colorectal Cancer (mCRC)
• Phase III CORRECT Trial of Regorafenib in Metastatic Colorectal Cancer (mCRC)
• Final Analysis of the Phase III Randomized Trial of Cetuximab (CET) Plus Either Brivanib Alaninate (BRIV) or Placebo in Patients (pts) With Chemotherapy Refractory, K-RAS Wild-Type (WT), Metastatic Colorectal Carcinoma (mCRC): The NCIC Clinical Trials Group and AGITG CO.20 trial
• Effects of Prior Bevacizumab (B) Use on Outcomes From the VELOUR study: A Phase III Study of Aflibercept (Afl) and FOLFIRI in Patients (pts) With Metastatic Colorectal Cancer (mCRC) After Failure of an Oxaliplatin Regimen
• FOLFOX4 (12 cycles) Versus Sequential Dose-Dense FOLFOX7 (6 cycles) Followed by FOLFIRI (6 cycles) in Patients With Initially Resectable Metastatic Colorectal Cancer: A GERCOR Randomized Phase III Study (MIROX)
PLUS Meeting Abstract Summaries

June 2012:

Clinical Roundtable Monograph: Disease State Awareness in Gaucher Disease: A Q&A Expert Roundtable Discussion

Pramod K. Mistry, MBBS, PhD, FRCP, MA, Joel A. Weinthal, MD, and Neal J. Weinreb, MD, FACP

Abstract: Gaucher disease is an inherited lysosomal storage disorder caused by mutations in the gene that encodes the lysosomal enzyme glucocerebrosidase. Inadequate enzymatic activity causes cells to become engorged due to an accumulation of glycolipids. Engorged cells then accumulate in various organs, resulting in a range of signs and symptoms. Gaucher disease occurs worldwide but is more common among individuals of Ashkenazi Jewish descent. Approximately 90% of patients with Gaucher disease have non-neuronopathic (type 1) disease, which is characterized by hematologic sequelae, potentially disabling skeletal complications, and late-onset neurologic complications. The other 2 subtypes of Gaucher disease cause neuronopathic disease, with early involvement of the central nervous system. Type 2 Gaucher disease results in death in infancy, while type 3 disease causes variable neurologic manifestations ranging from minimal ocular effects to seizures, ataxia, and cognitive regression. Because of its relative rarity, Gaucher disease often remains misdiagnosed or undiagnosed for some time. However, early diagnosis and appropriate treatment are essential for reducing the risk of complications, improving quality of life, and avoiding inappropriate procedures. Given the prevalence of hematologic manifestations associated with this condition, patients with undiagnosed Gaucher disease may seek treatment from hematologists or oncologists. Therefore, hematology and oncology clinicians need to be aware of the potential for Gaucher disease and consider it in their differential diagnosis.

May 2012:

Clinical Roundtable Monograph: Cases in the Management of Chemotherapy-Induced Nausea and Vomiting: Integrating Updated Guidelines into Clinical Practice

Steven M. Grunberg, MD, Gary R. Morrow, PhD, MS, and Lee S. Schwartzberg, MD, FACP

Abstract: Chemotherapy-induced nausea and vomiting (CINV) is one of the most significant side effects of cancer treatment, impacting patients’ quality of life and treatment compliance and potentially necessitating changes in patients’ therapy. The optimal strategy for CINV management is prophylaxis; in fact, prevention of CINV—rather than management—is one of the major treatment paradigm changes that has occurred in recent decades. This knowledge, as well as a better understanding of the emetogenic potential of various chemotherapeutic agents and the varying risk factors associated with CINV, has led to major improvements in CINV prophylaxis. Several evidence-based guidelines now exist to guide clinicians regarding the best regimens for CINV prevention, and these guidelines have recently been updated to reflect the publication of major clinical trials and the approval of new agents. Incorporating these guidelines into clinical practice can provide clinicians with an excellent starting point for CINV management, but clinicians must also be familiar with the evidence upon which the guidelines are based in order to alter antiemetic regimens as needed for individual patients. Additionally, clinicians should understand many of the special considerations related to CINV, such as the fact that chemotherapy-induced nausea is actually more frequent than chemotherapy-induced vomiting. Finally, several nontraditional therapies are available as alternative strategies for patients who do not benefit from currently approved antiemetic agents.

Clinical Roundtable Monograph: Recent Advances in Radioimmunotherapy in the Treatment of Follicular Lymphoma

Stephanie A. Gregory, MD, Mark S. Kaminski, MD, and John M. Pagel, MD, PhD

Abstract: Follicular lymphoma is the second most common non-Hodgkin lymphoma and the most common indolent lymphoma. It often presents at an advanced stage. Major advances have occurred in the therapy of all B-cell lymphomas with the approval in 1997 of the monoclonal antibody rituximab. However, in general, the disease is not curable. The disease is heterogeneous and there is no standard of care; therefore, therapy should be individualized. One needs to look at both patient and disease characteristics. In the asymptomatic patient with low tumor burden, “watch and wait” is an appropriate choice. However, patients with high tumor burden or symptoms require immediate therapy, usually with chemoimmunotherapy or, on occasion, monotherapy with rituximab. Radioimmunotherapy (RIT) has been used with very promising results as a single agent for frontline treatment; however, single-agent RIT in the upfront setting should be used only as part of a clinical trial. Relapsed disease, likewise, has many options for therapy, but RIT is an effective treatment, especially if used early before the patient has been treated with many regimens. The radioimmunotherapeutics 131I-tositumomab and 90Y-ibritumomab tiuxetan are approved to treat relapsed and refractory lymphoma. RIT has achieved prolonged remissions, which are more likely when patients are treated early rather than as last-line treatment. RIT has also been used as part of the preparative regimen for stem cell transplantation. The 2 main approaches for RIT and stem cell transplantation involve nonablative doses of radiolabeled antibodies combined with high-dose chemotherapy, or high doses of radiolabeled antibodies consisting of myeloablative doses of either 131I-tositumomab or 90Y-ibritumomab tiuxetan combined with high-dose chemotherapy.

April 2012:

Clinical Roundtable Monograph: Emerging Treatment Options for Relapsed and Refractory Multiple Myeloma: A Post-ASH Discussion

David S. Siegel, MD, PhD, Sundar Jagannath, MD, and Ruben Niesvizky, MD

Abstract: Multiple myeloma is the second most common hematologic malignancy. Almost all patients who survive initial treatment will eventually relapse and require further therapy. Despite the availability of newer drugs such as bortezomib and lenalidomide, patients with relapsed or refractory multiple myeloma continue to have very limited treatment options and a restricted life expectancy. Several agents that have shown promise in treating relapsed or refractory multiple myeloma patients are currently in phase III clinical trials. Some of these novel agents work through new mechanisms, whereas others represent the next generation of existing medications. Agents with acceptable efficacy and low toxicity are better suited for relapsed patients who receive consecutive therapies. Moreover, agents with new mechanisms may be judiciously combined with existing agents to avoid overlapping toxicities.

Highlights in Advanced Prostate Cancer From the 2012 ASCO Genitourinary Cancers Symposium

Daniel Petrylak, MD

Special Reporting on:
• An Analysis to Quantify the Benefit of Sip-T Accounting for the Crossover in the Control Arm of the IMPACT Study
• Effect of MDV3100, an Androgen Receptor Signaling Inhibitor (ARSI), on Overall Survival in Patients With Prostate Cancer Postdocetaxel: Results From the Phase III AFFIRM Study
• Approved Agents and Related Trials in Castration-Resistant Prostate Cancer
• Optimal Sequencing of Agents in Castration-Resistant Prostate Cancer
• Novel Targets, Agents, and Trials in Castration-Resistant Prostate Cancer
• Sipuleucel-T Product Characterization Across Different Disease States of Prostate Cancer

March 2012:

Highlights in T-Cell Lymphoma From the 2011 American Society of Hematology Annual Meeting and Exposition

Steven M. Horwitz, MD

A Review of Selected Presentations From the 53rd Annual Meeting and Exposition
December 10-13, 2011 • San Diego, California

February 2012:

Highlights in Metastatic Breast Cancer From the 2011 San Antonio Breast Cancer Symposium (SABCS)

Charles L. Vogel, MD

• Everolimus for Postmenopausal Women With Advanced Breast Cancer
• The Addition of Pertuzumab to Trastuzumab and Docetaxel in Patients With Previously Untreated HER2-Positive Metastatic Breast Cancer
• Neoadjuvant Pertuzumab and Trastuzumab With or After an Anthracycline-Containing or Anthracycline-Free Standard Regimen
• Neoadjuvant Pertuzumab and Trastuzumab: Biomarker Analyses
• Neratinib Versus Lapatinib Plus Capecitabine for HER2-Positive Locally Advanced or Metastatic Breast Cancer
• Anastrozole Versus Anastrozole and Fulvestrant as First-Line Therapy for Postmenopausal Women With Metastatic Breast Cancer
• Trials of Bisphosphonates in Breast Cancer

Highlights in Lymphoma From the 2011 American Society of Hematology (ASH) Annual Meeting

Anas Younes, MD

• Frontline Therapy With Brentuximab Vedotin Combined With ABVD or AVD in Newly Diagnosed Advanced Stage Hodgkin Lymphoma
• Brentuximab Vedotin in Systemic Anaplastic Large Cell Lymphoma
• Ponatinib in Patients With Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia
• Analysis of Patients With Common PTCL Subtypes From a Phase II Study of Romidepsin
• Obinutuzumab Monotherapy in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

December 2011:

The Role of Surrogate Markers in the Management of Men With Metastatic Castration-Resistant Prostate Cancer

Andrew J. Armstrong, MD, ScM, Anna C. Ferrari, MD, David I. Quinn, MD

November 2011:

Recent Advances and Updated Guidelines in the Management of Chemotherapy-Induced Nausea and Vomiting

Lee S. Schwartzberg, MD, FACP, Steven M. Grunberg, MD, Mark G. Kris, MD

Peripheral T-Cell Lymphomas: Diagnosis and Treatment Options

Bruce D. Cheson, MD, Steven M. Horwitz, MD, Dennis D. Weisenburger, MD

Volume 9, Issue 11, Supplement 26  November 2011 Peripheral T-Cell Lymphomas: Diagnosis and Treatment Options Proceedings From a Live Roundtable, August 17, 2011, Kauai, Hawaii Moderator […]

Current Treatment Options for Metastatic Breast Cancer: What Now?

Hope S. Rugo, MD, Joyce A. O’Shaughnessy, MD, Edith A. Perez, MD

October 2011:

Highlights From the Pan Pacific Lymphoma Conference

Bruce D. Cheson, MD

Volume 9, Issue 10, Supplement 24 October 2011

September 2011:

Highlights in NSCLC From the IASLC 14th World Conference on Lung Cancer

Roy S. Herbst, MD, PhD

Volume 9, Issue 9, Supplement 23 September 2011

Clinical and Laboratory Features of Myelofibrosis and Limitations of Current Therapies

Stephanie A. Gregory, MD, Ruben A. Mesa, MD, Ronald Hoffman, MD, Jamile M. Shammo, MD

Volume 9, Issue 9, Supplement 22 September 2011

August 2011:

New Frontiers and Treatment Paradigms for Metastatic Breast Cancer

Edith A. Perez, MD, Susan Mooberry, PhD, Christopher Twelves, MD, Hope S. Rugo, MD

Volume 9, issue 8, supplement 20 august 2011

Bendamustine: Mechanism of Action and Clinical Data

Bruce D. Cheson, MD, Lorenzo Leoni, PhD

Volume 9, Issue 8, Supplement 19 August 2011

Highlights in NSCLC From the American Society of Clinical Oncology Meeting

Mark. A. Socinski, MD

Volume 9, Issue 8, Supplement 18 August 2011

Summer Happenings in Hematology 2011

Elizabeth Ashforth, PhD, Bruce D. Cheson, MD

Volume 9, issue 8, supplement 17 august 2011

Current Treatment of Peripheral T-Cell Lymphoma

Steven M. Horwitz, MD, Bertrand Coiffier, MD, Eric D. Hsi, MD, Barbara Pro, MD

Volume 9, Issue 8, Supplement 16 August 2011

July 2011:

Accurate Reporting of Adverse Events in Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma

Bruce D. Cheson, MD, Kanti R. Rai, MD, Jonathan W. Friedberg, MD

Volume 9, Issue 7, Supplement 15 July 2011

The Relationship Between Symptomatology and Treatment Selection in Metastatic Castrate-Resistant Prostate Cancer

Eric J. Small, MD, David F. Penson, MD, MPH, Oliver Sartor, MD

Volume 9, Issue 7, Supplement 13 July 2011

June 2011:

New and Emerging Treatments for Advanced Prostate Cancer

Daniel J. George, MD, Philip W. Kantoff, MD, Daniel W. Lin, MD

Volume 9, Issue 6, Supplement 12 June 2011

May 2011:

Recent Advances in the Treatment of Breast Cancer: Highlights From the 2010 San Antonio Breast Cancer Symposium

Edith Perez, MD, Harold J. Burstein, MD, PhD, Clifford Hudis, MD

Volume 9, Issue 5, Supplement 11 May 2011

Novel Treatment Options in the Management of Metastatic Breast Cancer

Christopher Twelves, MD, Linda T. Vahdat, MD, Javier Cortés, MD, PhD

Volume 9, Issue 5, Supplement 10 May 2011

April 2011:

Peripheral T-Cell Lymphoma: A Case-Based Discussion of Recent Advances in Patient Management

Carlos M. Franco, MD, Leslie L. Popplewell, MD, Steven M. Horwitz, MD

Volume 9, issue 4, Supplement 9 April 2011

Recent Advances in the Treatment of T-Cell Lymphoma

Barbara Pro, MD

volume 9, issue 4, supplement 8 April 2011

Recent Advances in the Treatment of Leukemia, Lymphoma, and Myeloma

Bruce D. Cheson, MD

Volume 9, issue 4, Supplement 7 april 2011

Emerging Treatment Options for Relapsed and Refractory Multiple Myeloma

David S. Siegel, MD, PhD, Ravi Vij, MD, Andrzej J. Jakubowiak, MD, PhD

Volume 9, Issue 4, Supplement 6 April 2011

Emerging Therapeutic Options for Platinum-Sensitive Ovarian Cancer Patients

Deborah K. Armstrong, MD, Robert L. Coleman, MD, Richard T. Penson, MD, MRCP

Volume 9, Issue 4, Supplement 5 April 2011

March 2011:

Recent Advances in the Treatment of Multiple Myeloma

Sundar Jagannath, MD

volume 9, issue 3, supplement 4 march 2011

February 2011:

Early Death in Patients With Acute Promyelocytic Leukemia

Martin S. Tallman, MD, Francesco Lo-Coco, MD, Hau C. Kwaan, MD, PhD, Miguel A. Sanz, MD, PhD, Steven D. Gore, MD

Volume 9, Issue 2, Supplement 3 February 2011

January 2011:

Treatment of Chemotherapy-Induced Nausea and Vomiting: A Post-MASCC 2010 Discussion

Mark G. Kris, MD, Susan G. Urba, MD, Lee S. Schwartzberg, MD

Volume 9, Issue 1, Supplement 2 January 2011

The Oncologist’s Role in the Management of Venous Thromboembolism

Howard A. Liebman, MD, Alok A. Khorana, MD, Craig M. Kessler, MD

Volume 9, Issue 1, Supplement 1 January 2011

December 2010:

The Management of Aggressive T-cell Lymphoma: A Discussion on Transformed Mycosis Fungoides

Steven M. Horwitz, MD, Madeleine Duvic, MD, Eric D. Hsi, MD

T-cell Lymphoma: Therapeutic Overview and Disease State Awareness

James O. Armitage, MD, Eric D. Hsi, MD, Francine M. Foss, MD

October 2010:

Evolving Immunotherapy to Improve Survival for Patients With Non-Hodgkin Lymphoma

Martin H. Dreyling, MD, PhD, Myron S. Czuczman, MD, Peter McLaughlin, MD, Thomas E. Witzig, MD

September 2010:

August 2010:

New Frontiers in the Science and Management of Metastatic Breast Cancer

Javier Cortes, MD, Mary Ann Jordan, PhD, Joseph A. Sparano, MD

New Alternatives in CLL Therapy: Managing Adverse Events

Asher Chanan-Khan, MD, Thomas Kipps, MD, PhD, Stephan Stilgenbauer, MD, PhD

Another Summer of Hematology

Elizabeth Ashforth, PhD, Bruce D. Cheson, MD

Lipid-based Amphotericin B Formulations in Opportunistic Infections

Cornelia Lass-Flörl, MD, Nina Singh, MD, Ivica Knezovic, MD

July 2010:

B-cell Non-Hodgkin Lymphoma: A Case-based Discussion of Recent Advances in Patient Management

Myron S. Czuczman, MD, Stephanie A. Gregory, MD, Richard van der Jagt, MD

June 2010:

Current Management and Treatment of T-cell Lymphoma: A Multidisciplinary Approach

Barbara Pro, MD, Steven M. Horwitz, MD, Jill P. Atmar, RN, MSN, ANP-BC

Chronic Lymphocytic Leukemia: A Case-based Discussion of Recent Advances in Patient Management

Kanti R. Rai, MD, Wolfgang U. Knauf, MD, PhD, Bruce D. Cheson, MD

May 2010:

Recent Advances in the Management of Chemotherapy-induced Nausea and Vomiting: A Case Study Compendium

Gary R. Morrow, PhD, MS, Paul J. Hesketh, MD, Lee S. Schwartzberg, MD, FACP, David S. Ettinger, MD, FACP, FCCP

April 2010:

Recent Advances in the Treatment of Mantle Cell Lymphoma: A Post–ASH 2009 Discussion

Myron S. Czuczman, MD, John P. Leonard, MD, Michael E. Williams, MD

Recent Advances in the Management of Hematologic Malignancies

Elizabeth Ashforth, PhD, Bruce D. Cheson, MD

March 2010:

February 2010:

Recent Advances in the Treatment of T-cell Lymphomas

Owen A. O’Connor, MD, PhD

Volume 8, Issue 2, Supplement 4

Recent Advances in NHL

Myron S. Czuczman, MD, Mathias J. Rummel, MD, PhD

Volume 8, Issue 2, Supplement 3  February 2010

January 2010:

Clinical Considerations for Older Patients With Glioblastoma

Lauren E. Abrey, MD, Fabio M. Iwamoto, MD, Thomas Finnegan, PhD

Augmenting Clinical Responses through Intracellular Pathways in B-cell Malignancies

Myron S. Czuczman, MD, Anton Hagenbeek, MD, PhD, Bruce D. Cheson, MD, Andre Goy, MD, Nikhil C. Munshi, MD, Apostolia M. Tsimberidou, MD, PhD

Volume 8, Issue 1, Supplement 2

December 2009:

Recent Advances in Chronic Lymphocytic Leukemia: A Post-iwCLL 2009 Discussion

Kanti R. Rai, MD, Wolfgang U. Knauf, MD, PhD, John G. Gribben, MD, DSc

November 2009:

October 2009:

Current Management of Thromboembolism in Cancer Patients: Building a Consensus Abstract

Craig M. Kessler, MD, Gary H. Lyman, MD, MPH, FRCP, Ajay K. Kakkar, MD

Finding the Right Dose: Improving Patient Outcomes in CLL and NHL

Bruce D. Cheson, MD, Jonathan W. Friedberg , MD, Mathias J. Rummel, MD, PhD

September 2009:

A Summer of Hematologic Science

Bruce D. Cheson, MD, Elizabeth Ashforth, PhD

August 2009:

Evolving Strategies in the Treatment of MDS and AML

Richard Stone, MD, Mikkael Sekeres, MD, MS, Guillermo Garcia-Manero, MD

July 2009:

Treatment Selection for Myelodysplastic Syndrome Patients in the Community Setting

Lewis R. Silverman, MD, Roger M. Lyons, MD, FACP, Jamile M. Shammo, MD, FASCP, Bart L. Scott, MD

June 2009:

Emerging Treatment Options in Adult Acute Myelogenous Leukemia

Elihu H. Estey, MD, Wendy Stock, MD, Jerald P. Radich, MD

May 2009:

New Opportunities for the Management of Cancer-Related Bone Complications

Allan Lipton, MD, Gordon A. Brown, DO, Gregory R. Mundy, MD, G. David Roodman, MD, PhD, Matthew R. Smith, MD, PhD

April 2009:

Safety and Efficacy of Lipid-based Amphotericin B

Romuald Bellmann, MD, John D. Cleary, PharmD, FCCP, Jaroslav Sterba, MD, PhD

A Multidisciplinary Approach to The Use of Oncotype DX in Clinical Practice

William J. Gradishar, MD, Nora M. Hansen, MD, Barbara Susnik, MD, PhD

March 2009:

Hematologic Malignancies in the Aging Population: Biology, Molecular Prognostic Markers, and Novel Treatment Strategies

Bruce D. Cheson, MD, Harry P. Erba, MD, PhD, Kanti R. Rai, MD, Bart Barlogie, MD, PhD, Mathias J. Rummel, MD, PhD

February 2009:

The Evolving Role of Multifunctional Agents in Lymphoid Malignancies

David G. Maloney, MD, PhD, Bruce D. Cheson, MD, Mathias J. Rummel, MD, PhD, Jonathan W. Friedberg, MD, Kanti R. Rai, MD, Michael Hallek, MD

Monitoring Blood Plasma Concentrations to Improve Outcomes in CML and GIST

Merrill J. Egorin, MD, Richard A. Larson, MD, George D. Demetri, MD

Recent Advances in the Treatment of Hematologic Malignancies

Shaji Kumar, MD, S. Vincent Rajkumar, MD, John P. Leonard, MD, Kanti R. Rai, MD, Guillermo Garcia-Manero, MD

January 2009:

Hodgkin Lymphoma: Advancing Beyond Standard Management

Bruce D. Cheson, MD, FACP, Volker Diehl, MD, Anas Younes, MD, John Radford, MD

Advancing CML Patient Care: Closing in on a Cure?

Francis J. Giles, MB, MD, FRCPI, FRCPath, Michael J. Mauro, MD, Jerald P. Radich, MD, Moshe Talpaz, MD

Emerging Strategies in Regulatory T-cell Immunotherapies

Thomas F. Gajewski, MD, PhD, Jason Chesney, MD, PhD, Tyler J. Curiel, MD, MPH

December 2008:

Recent Advances in Low- and Intermediate-1–Risk Myelodysplastic Syndrome: Developing a Consensus for Optimal Therapy

Richard Stone, MD, Mikkael Sekeres, MD, MS, Guillermo Garcia-Manero, MD, Roger M. Lyons, MD, FACP

Romidepsin in the Treatment Of Hematologic Malignancies

H. Miles Prince, MD, Bertrand Coiffier, MD, Ellen J. Kim, MD, Alain H. Rook, MD

November 2008:

AML: Current and Emerging Treatment Approaches

Martin Tallman, MD, Steven D. Gore, MD, Judith Karp, MD

September 2008:

Recent Advances in the Treatment of Non-Hodgkin Lymphoma

Bruce D. Cheson, MD, Jonathan Friedberg, MD, Steven Rosen, MD

August 2008:

May 2008:

Managing Patients With Acute Myeloid Leukemia— Importance of Supportive Care Measures

Amar Safdar, MD, FACP, Alex Castellino, PhD, Jacob M. Rowe, MD, FACP

Chronic Lymphocytic Leukemia: Current and Emerging Treatment Approaches

Bruce D. Cheson, MD, Kanti R. Rai, MD, Susan O’Brien, MD

Strategies for the Management of Iron Overload in the Transplant Setting

Richard J. O’Reilly, MD, Emanuele Angelucci, MD, Mark Walters, MD, Deborah Chirnomas, MD

April 2008:

Translating Biology to Clinical Practice: Evolving Strategies for the Treatment of Renal Cell Carcinoma

Ronald Bukowski, MD, Christopher Wood, MD, David Quinn, MD, PhD, FRACP, Thomas Hutson, DO, PharmD, FACP

March 2008:

Current Treatment Strategies for Myelodysplastic Syndromes

David P. Steensma, MD, Kenneth Miller, MD, German Pihan, MD, Elias Jabbour, MD, Mikkael A. Sekeres, MD, MS, Larry D. Cripe, MD

February 2008:

January 2008:

New Strategies in the Treatment of T-Cell Lymphoma

H. Miles Prince, MD, FRACP, FRCPA

View More Supplements